



Editorial



The immune system in Parkinson's disease: From biology to diagnosis and therapeutic targets

Parkinson's disease (PD) is a complex and heterogeneous progressive neurodegenerative condition known for characteristic motor features resulting from the loss of dopaminergic neurons from the substantia nigra. However, the broad range of clinical manifestations demonstrates that PD is more than just a movement disorder affecting peripheral organs such as the heart and gut. At the neuropathological level, PD is characterized by the accumulation of alpha-synuclein (aSyn) positive inclusions known as Lewy bodies and Lewy neurites. However, the causal role of Lewy pathology in PD, as well as in other synucleinopathies, has not been definitively established, demanding urgent efforts towards our understanding of the molecular underpinnings of PD. Original studies employing post-mortem human brain tissue showed neuroinflammatory responses in the PD brain. Subsequently, inflammatory processes can also be detected in peripheral blood and the cerebrospinal fluid (CSF). Notably, several genetic alterations in modulators of immune responses have been associated with either familial forms of PD or increased risk for developing PD. Thus, it is evident that the interplay between the immune system and PD is a topic of great interest.

Weiss et al. start by providing a general overview of the immune responses in the PD brain (Weiss et al., 2022). They explore the evidence for different astrocytic responses and describe the occurrence of infiltration of peripheral immune cells in the PD brain, as observed in post-mortem studies, and how these responses play a role in neuronal cell death.

Bartl et al. discuss recent evidence confirming immune system alterations and that this can be detected by monitoring peripheral biological fluids, where chronic pro-inflammatory signals can be measured (Bartl et al., 2022). The precise origin of this chronic inflammation is still unclear. Still, it may arise due to alterations in the gut microbiome, which could enhance immune cell responses, thereby fuelling inflammation. They propose that studies using large patient cohorts and control groups will be important to further validate existing findings and aid the discovery of novel biomarkers.

Amin et al. focus on the role of inflammation in dementia with Lewy bodies (DLB), the second most common type of neurodegeneration-associated dementia, after Alzheimer's disease (Amin et al., 2022). This is an insightful review, as our understanding of the role of inflammation in DLB is still limited. The authors cover evidence derived from the use of different methodologies in a variety of biological fluids and also from PET imaging and neuropathological examination of post-mortem brain tissue. Overall, the authors argue that aSyn directly promotes inflammation but significantly, raise the point that AD co-pathology is also an important factor contributing to neuroinflammation in DLB.

Stoll and Sortwell then explore how pre-clinical studies using the preformed fibril (PFF) model of aSyn are enabling studies aimed at dissecting the contribution of aSyn pathology or nigrostriatal degeneration to immune system activation and neuroinflammation (Stoll and Sortwell, 2022). On one hand, existing findings suggest that aSyn pathology is immunogenic itself. Still, longitudinal studies will be necessary to establish further the source of inflammatory stimuli that trigger the different types of responses. In this context, the PFF model emerges as a useful model to investigate these issues in laboratory models *in vivo*.

Domingues et al. focus on the effects that extracellular aSyn species, which exist as a corollary of the prion-like spreading hypothesis, may have (Domingues et al., 2022). In particular, they discuss how such aSyn species may be sensed by cells, which proteins appear to act as receptors, what signaling responses may be elicited, and their biological effects. They highlight effects on the glial-neuronal interface, as this may be particularly relevant for spreading aSyn pathology.

Abdi et al. discuss evidence suggesting that immune-related alterations may be useful as biomarkers for PD (Abdi et al., 2022). Since the immune system appears to play a role in the pathology of PD, supporting the idea of an interaction between the periphery and the central nervous system, it is likely that markers of immune system activation in the periphery may report on disease-specific alterations that can be used as markers of diagnosis as well as of disease progression.

Gopinath et al. present a critical overview of the role of inflammation and gliotransmitters in PD (Gopinath et al., 2022). They start by highlighting our limited understanding of the role of innate and adaptive immune cell function in brain health and then argue that identifying immune and inflammatory pathways that impact neuronal function, health, and survival will be critical for the design of strategies that limit their effects to modify or prevent brain diseases such as PD.

Russo et al. focus on a key player in PD due to its association with familial and sporadic disease forms - the LRRK2 protein. In particular, they discuss how LRRK2 can be used as a target for modulating immune system responses, as mutations in LRRK2 have been found in a wider group of patients with immune-related disorders (Russo et al., 2022). They discuss how LRRK2 inhibitors and anti-inflammatory drugs may be beneficial for reducing disease risk and progression in mutation carriers and PD patients.

Mamais et al. explore the evidence supporting the convergence of signaling pathways in innate immune responses and genetic forms of PD (Mamais et al., 2022). They discuss how signaling pathways associated with genetic forms of PD are also relevant to inflammatory signaling pathways, such as the MAPK, NF- κ B, Wnt, and inflammasome signaling, as demonstrated by post-mortem analyses of brain tissue and by studies using cerebrospinal fluid (CSF) from PD patients.

<https://doi.org/10.1016/j.nbd.2023.105995>

Available online 7 January 2023

0969-9961/© 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Tsafaras and Baekelandt also provide their views on the connection between PD and inflammatory diseases by focusing on the role of LRRK2 in the periphery (Tsafaras and Baekelandt, 2022). In particular, they discuss the possible role of LRRK2 in spreading aSyn pathology and its role in peripheral inflammation. This understanding should inform on the mechanisms involved in PD and the connection between PD and other inflammatory diseases.

Finally, Karampetsou et al. explore the TGF- β superfamily as a target for therapeutic intervention, given its regulatory role in the central nervous system (Karampetsou et al., 2022). Since, TGF- β signaling pathways are involved in the differentiation and maintenance of synaptic function in dopaminergic neurons, which are particularly affected in PD, and also in the activation of astrocytes and microglia, the TGF- β superfamily is positioned at the interface between inflammation and PD. The authors discuss how studies in animal models have been important for assessing the value of targeting this family of proteins as targets for therapeutic intervention.

Taken together, immune response-associated alterations hold promise as biomarkers and targets for therapeutic intervention. This is the thread of this special issue, and we are confident it will inspire additional research on this important topic.

References

- Abdi, I.Y., Ghanem, S.S., El-Agnaf, O.M., 2022 Aug. Immune-related biomarkers for Parkinson's disease. *Neurobiol. Dis.* 170, 105771 <https://doi.org/10.1016/j.nbd.2022.105771>. Epub 2022 May 19. PMID: 35598675.
- Amin, J., Erskine, D., Donaghy, P.C., Surendranathan, A., Swann, P., Kunicki, A.P., Boche, D., Holmes, C., McKeith, I.G., O'Brien, J.T., Teeling, J.L., Thomas, A.J., 2022 Jun 15. Inflammation in dementia with Lewy bodies. *Neurobiol. Dis.* 168, 105698 <https://doi.org/10.1016/j.nbd.2022.105698> (Epub 2022 Mar 18. PMID: 35314318).
- Bartl, M., Xylaki, M., Bähr, M., Weber, S., Trenkwalder, C., Mollenhauer, B., 2022 Aug. Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease. *Neurobiol. Dis.* 170, 105744 <https://doi.org/10.1016/j.nbd.2022.105744>. Epub 2022 May 2. PMID: 35513230.
- Domingues, R., Sant'Anna, R., da Fonseca, A.C.C., Robbs, B.K., Foguel, D., Outeiro, T.F., 2022 Jun 15. Extracellular alpha-synuclein: sensors, receptors, and responses. *Neurobiol. Dis.* 168, 105696 <https://doi.org/10.1016/j.nbd.2022.105696> (Epub 2022 Mar 20. PMID: 35321855).
- Gopinath, A., Mackie, P.M., Phan, L.T., Tansey, M.G., Khoshbouei, H., 2022 Dec 5. The complex role of inflammation and gliotransmitters in Parkinson's disease. *Neurobiol. Dis.* 176, 105940 <https://doi.org/10.1016/j.nbd.2022.105940> (Epub ahead of print. PMID: 36470499).
- Karampetsou, M., Vekrellis, K., Melachroinou, K., 2022 Sep. The promise of the TGF- β superfamily as a therapeutic target for Parkinson's disease. *Neurobiol. Dis.* 171, 105805 <https://doi.org/10.1016/j.nbd.2022.105805>. Epub 2022 Jun 25. PMID: 35764291.
- Mamais, A., Kaganovich, A., Harvey, K., 2022 Jul. Convergence of signalling pathways in innate immune responses and genetic forms of Parkinson's disease. *Neurobiol. Dis.* 169, 105721 <https://doi.org/10.1016/j.nbd.2022.105721>. Epub 2022 Apr 8. PMID: 35405260.
- Russo, I., Bubacco, L., Greggio, E., 2022 Jul. LRRK2 as a target for modulating immune system responses. *Neurobiol. Dis.* 169, 105724 <https://doi.org/10.1016/j.nbd.2022.105724>. Epub 2022 Apr 12. PMID: 35427743.
- Stoll, A.C., Sortwell, C.E., 2022 Sep. Leveraging the preformed fibril model to distinguish between alpha-synuclein inclusion- and nigrostriatal degeneration-associated immunogenicity. *Neurobiol. Dis.* 171, 105804 <https://doi.org/10.1016/j.nbd.2022.105804>. Epub 2022 Jun 25. PMID: 35764290.
- Tsafaras, G., Baekelandt, V., 2022 Oct 1. The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases. *Neurobiol. Dis.* 172, 105806 <https://doi.org/10.1016/j.nbd.2022.105806> (Epub 2022 Jun 30. PMID: 35781002).
- Weiss, F., Labrador-Garrido, A., Dzamko, N., Halliday, G., 2022 Jun 15. Immune responses in the Parkinson's disease brain. *Neurobiol. Dis.* 168, 105700 <https://doi.org/10.1016/j.nbd.2022.105700> (Epub 2022 Mar 18. PMID: 35314321).
- Tiago Fleming Outeiro^{a,b,c,d,*}, Omar M. El-Agnaf^{e,f,**}
^a Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany
^b Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany
^c Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK
^d Scientific Employee with an Honorary Contract at Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen, Germany
^e Neurological Disorder Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar
^f Biological and Biomedical Sciences Division, College of Health & Life Sciences, Hamad Bin Khalifa University, Doha, Qatar
- * Correspondence to: T.F. Outeiro, Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.
- ** Correspondence to: O.M. El-Agnaf, Neurological Disorder Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation, Doha, Qatar.
- E-mail addresses: touteir@gwdg.de (T.F. Outeiro), aelagnaf@hbku.edu.qa (O.M. El-Agnaf).